KO Client Elpida Therapeutics Licenses Ionis ION283 to Advance Treatment for Ultra-Rare Disorder

KO client Elpida Therapeutics, a nonprofit biotechnology company dedicated to developing treatments for ultra-rare pediatric neurological diseases, recently announced that it has entered into an assignment and license agreement with Ionis Pharmaceuticals for ION283, an investigational antisense oligonucleotide (ASO) therapy for Lafora disease.

The agreement is expected to advance the clinical development of this investigational therapy for Lafora disease, an ultra-rare, progressive, and fatal neurodegenerative disorder with no approved disease-modifying therapies.

“For families living with Lafora disease, every day matters. We are incredibly grateful to Ionis for their years of scientific innovation and for entrusting Elpida with the next chapter of this program,” said Terry Pirovolakis, Founder & Chief Executive Officer of Elpida Therapeutics in the announcement. “Our commitment is simple: move as quickly as possible, work collaboratively with the global clinical community, and do everything we can to bring this therapy to every patient.”

KO partner Brad Schoenfeld and attorney John Shearer represented Elpida in the agreement. Read more in the press release.